Carcino Embryonic Antigen CEA抗体;Carcino Embryonic Antigen CEA Antibody—艾普蒂 新品

+ +

•  

   

     Immunofluorescence analysis of Carcino Embryonic Antigen CEA in Human lungcancer tissue using Carcino Embryonic Antigen CEA antibody(red),and DAPI (blue).    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human liver tissue using Carcino Embryonic Antigen CEA antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.Negative control was used by secondary antibody only.    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human colon cancer tissue using Carcino Embryonic Antigen CEA antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

Carcinoembryonic antigen (CEA), also known as CEACAM5. is a glycoprotein belonging to the immunoglobulin superfamily, first identified in 1965 as an oncofetal antigen expressed during fetal development and suppressed in most adult tissues. It re-emerges in elevated concentrations in various cancers, particularly colorectal, pancreatic, gastric, lung, and breast malignancies, making it a widely studied tumor biomarker. CEA plays roles in cell adhesion, immune modulation, and metastasis promotion, though its exact physiological functions remain incompletely understood.

CEA antibodies, primarily monoclonal antibodies (mAbs), have been developed for diagnostic, prognostic, and therapeutic applications. In diagnostics, anti-CEA antibodies are used in immunoassays (e.g., ELISA, immunohistochemistry) to detect CEA levels in serum or tissue samples, aiding cancer screening, staging, and recurrence monitoring. Elevated serum CEA correlates with tumor burden and poor prognosis. Therapeutically, CEA-targeting antibodies are explored in radioimmunotherapy, antibody-drug conjugates (ADCs), and bispecific antibodies to deliver cytotoxic agents or recruit immune cells. Challenges include CEA's heterogeneity, low tumor specificity (elevated in benign conditions like inflammation), and potential immunogenicity.

Recent advances involve engineering humanized or fully human anti-CEA antibodies to minimize adverse effects and improve targeting efficiency. Additionally, CEA-based vaccines and CAR-T therapies are under investigation. Despite limitations, CEA remains a cornerstone in cancer management, with antibodies serving as vital tools for both clinical practice and research into tumor biology. Ongoing studies aim to refine their specificity and integrate CEA-targeting strategies into multimodal cancer therapies.